Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatolog…

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...
Business Recorder

Is Pakistan braced for next shock?

Pakistan primarily imports Di-Ammonium Phosphate (DAP), Nitrogen Phosphate Potassium (NPK) to fulfill agriculture needs. Due ...
Pharmabiz

Takeda presents positive data from two pivotal phase 3 studies of zasocitinib to treat adults with moderate-to-severe plaque psoriasis at AAD meeting

71.4% and 69.2% of patients treated with zasocitinib achieved a static Physician Global Assessment (sPGA) score of 0/1 versus placebo (10.7% and 12.6%) and apremilast (32.1% and 29.7%) at week 16 (p<0 ...

ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

Johnson & Johnson (NYSE: JNJ) today announced new long-term 52-week data from the Phase 3 ICONIC-ADVANCE 1 and 2 and ICONIC-LEAD studies, which assessed the efficacy and safety of ICOTYDE™ ...
Las Vegas Sun

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care

Mar 28, 2026-- Takeda ( TSE:4502/NYSE:TAK ) today announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279 ...
India Today

US-Israel-Iran War Highlights: White House touts limited Hormuz passage, insists peace talks continue

As the Iran-US-Israel conflict intensifies, multiple flashpoints are emerging across the region, signalling a dangerous ...
Falmouth Packet on MSN

Easyjet to start new routes from Cornwall this summer

One month after a decision was made to discontinue Skybus flights from Newquay to London, a major airline has announced it will now be offering a new connection to the capital ...

Protagonist Therapeutics: Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of ...

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasisResults furt ...
The Malaysian Reserve

UCB Presents New BIMZELX® (bimekizumab-bkzx) Data at AAD Demonstrating High Rates of Durable and Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis

Post hoc analyses of BIMZELX (bimekizumab-bkzx) using the first consensus definition of psoriasis on-treatment remission:Published by the National ...

Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis

EBGLYSS (lebrikizumab-lbkz) delivered durable skin clearance and relief from persistent itch for up to four years for ...
Pharmabiz

Lilly's Ebglyss delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis

Lilly's Ebglyss delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis: Indianapolis Monday, March 30, 2026, 12:00 Hrs [IST] ...